Morgan Stanley lowered the firm’s price target on Globus Medical (GMED) to $68 from $75 and keeps an Overweight rating on the shares. The firm continues to like the MedTech industry setup into Q2 on relative stability in procedure volumes and hospital capital expenditures across the space, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMED:
- Barclays bullish on Globus Medical, sees share upside to $103
- Globus Medical Approves Key Proposals at Annual Meeting
- Needham medtech & diagnostics analyst holds analyst/industry conference call
- AMD, Block upgraded: Wall Street’s top analyst calls
- Globus Medical downgraded to Neutral from Buy at BTIG